Ibritumomab tiuxetan is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.
- Mechanism
- Curator reviewed
The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.
- Primary indication
- For treatment of non-Hodgkin's lymphomaCurator reviewed · 3 structured indications
- Formula / weight
- C6382H9830N1672O1979S54 · 143375.5 Da
- First approval
- United States, 2002
- Also known as
- Ibritumomab · mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)
- Code names
- IDEC-129 · IDEC-Y2B8
- Brand names
Resolves to
Compound
Clinical / RWD
Targets
What you can answer from here — as of July 17, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Ibritumomab tiuxetan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account